Bozic Carmen 4

What Happened Carmen Bozic, EVP and Chief Medical Officer of Vertex Pharmaceuticals (VRTX), sold 2,329 shares in an open-market transaction on 2026-03-27 at $450.95 per share, generating proceeds of approximately $1,050,263. This was a sale (not a purchase); sales by insiders are often routine cashing-out events rather than explicit buy/sell signals about the company’s prospects.

Key Details

• Transaction date and price: 2026-03-27 — sale of 2,329 shares at $450.95 each.
• Total value: ~ $1,050,263.
• Shares owned after transaction: Not provided in the information supplied.
• Footnote: Transaction was made pursuant to a company-approved Rule 10b5-1 trading plan established on 2025-11-20.
• Filing timeliness: Form 4 was filed on 2026-03-31 (filed within the required two business days following the transaction), so no late-filing flag.

Context

• The sale was executed under a pre-established 10b5-1 plan, which typically allows insiders to sell shares according to a preset schedule and helps separate trading decisions from current insider knowledge.
• For retail investors: purchases by insiders generally carry more direct informational weight than routine sales; a single planned sale does not necessarily indicate a change in insider view of the company.